Ketamine Media launches industry-leading psychedelic therapy network

Featured Image for Ketamine Media

Featured Image for Ketamine Media

KNOXVILLE, TN, Feb. 3 2022 (GLOBE NEWSWIRE) — Ketamine Media (Keta Media, LLC) is proud to announce the launch of its Psychedelic Therapy Network (PTN)a digital ecosystem connecting psychedelic drug providers with people seeking innovative new treatment options in the world of mental health.

Psychedelic Therapy Network (PTN) is the culmination of a long effort to provide patients seeking alternative care with a single point of reference and comprehensive resource for finding psychedelic drug providers in their areas. The collection of digital assets will effectively reach potential candidates in virtually every zip code in North America.

Ketamine backgrounds felt that the establishment of the network was an essential tool to spread awareness and education about psychedelic medicine. As the country faces one of the worst mental health crises in its history, new methods and modalities for dealing with mental health issues are needed.

“The Psychedelic Therapy Network was designed to help our partners effectively raise awareness at scale. But it’s really designed with patients in mind. When we created it [the Psychedelic Therapy Network], we wanted to take a patient-centric approach. The psychedelic medicine space can be confusing, and our team wanted to build something that helps people learn more about psychedelic medicine and unites them with qualified, passionate providers once they decide this approach is right for them. », said Chris Walden, CEO and co-founder of Ketamine Media.

Innovative new drugs derived from compounds such as psilocybin, MDMA and many more will soon join existing therapies such as ketamine-assisted psychotherapy to combat the nation’s crippling mental health issues. Psychedelic therapies like ketamine have shown the potential to be more effective than standard drugs like SSRIs, psilocybin, and MDMA showing similar or greater efficacy in some situations. In this spirit, the creation of a single global network was seen as an essential element in laying the foundations for the future.

Currently, the PTN serves primarily as a hub for patients to find providers who specialize in various forms of ketamine-assisted therapy and infusions. However, as drugs continue to be approved, such as MDMA (are currently entering phase three trials conducted by MAPS) and psilocybin (enter phase two trials with COMPASS Pathways), the network will expand to also cover medical providers offering these services.

Expanding access to new mental health treatments can provide significant benefits to the general public, but is of vital importance to the nation’s veteran population. Military veterans and first responders are 52% more likely to develop post-traumatic stress disorder (PTSD), a mental health condition associated with traumatic experiences. Veterans and first responders are also much more likely to suffer from depression and have much higher suicide rates than the general population.

“As a veteran who has dealt with PTSD and depression first hand, I can say that treatments like psilocybin, ketamine and MDMA work. Unlike many veterans, I have had the opportunity to experience the healing potential of psychedelics firsthand at retreats at legal centers.If veterans here at home (in the US) had access to this type of therapy, we would likely see a significant reduction in suicide rates and depression of veterans at all levels”, said David Connell, author of “Cooking with Magic: The Psilocybin Cookbook” and senior editor at Ketamine Media.

The potential benefits of psychedelic drugs go beyond veteran mental health care. End-of-life care, treatment-resistant depression, anxiety, and substance abuse disorders are just a few of the conditions that psychedelic compounds have shown promise for treating.

Tools like the Psychedelic Therapy Network will be a vital part of expanding the reach of psychedelic medicine providers as therapies such as ketamine-assisted psychotherapy, MDMA-assisted therapy, and psilocybin treatments gain traction. Patients and providers will benefit from the suite of tools, connections, and educational resources offered by the PTN, building public awareness and knowledge about these tools for tackling mental health issues.


Ketamine Media is a full-service multimedia marketing and advertising company headquartered in Knoxville, Tennessee. Specializing in raising awareness of the clinical use of ketamine and other psychedelic drugs, Ketamine Media is the nation’s oldest and most successful ketamine-focused advertising agency. The Ketamine Media team offers extensive experience communicating and connecting with people interested in exploring new treatments for their mental health care. This specialist know-how is invaluable to their partners within the space, who need to reach patients in critical need of specialist care.

For anyone interested in partnering with Ketamine Media, the company can be contacted at:

Ketamine backgrounds
611 King Street Northwest, Suite 200B
Knoxville, TN 37917
Phone: (800) 975-2291
In line:

Related images

Picture 1

This content was published via the press release distribution service.


Previous Banksea Finance announces the completion of its
Next Michigan potato growers vote to continue marketing program